Ferric pyrophosphate

Identification

Name
Ferric pyrophosphate
Accession Number
DB09147
Type
Small Molecule
Groups
Approved
Description

Ferric pyrophosphate, an iron replacement product, is a mixed-ligand iron complex in which iron (III) is bound to pyrophosphate and citrate.

Structure
Thumb
Synonyms
  • Iron pyrophosphate
  • Iron(III) pyrophosphate
Product Ingredients
IngredientUNIICASInChI Key
Ferric pyrophosphate citrateUBY79OCO9G1802359-96-1Not applicable
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
TrifericPowder272 mg/272mgParenteralRopack Inc.2016-11-28Not applicableUs
TrifericSolution272 mg/50mLHemodialysis; ParenteralRockwell Medical, Inc2015-09-04Not applicableUs
TrifericSolution5.44 mg/mLParenteralRockwell Medical, Inc2015-02-06Not applicableUs
TrifericPowder272 mg/1ParenteralRockwell Medical, Inc2016-04-25Not applicableUs
Categories
UNII
QK8899250F
CAS number
10058-44-3
Weight
Average: 745.21
Monoisotopic: 745.475544666
Chemical Formula
Fe4O21P6
InChI Key
CADNYOZXMIKYPR-UHFFFAOYSA-B
InChI
InChI=1S/4Fe.3H4O7P2/c;;;;3*1-8(2,3)7-9(4,5)6/h;;;;3*(H2,1,2,3)(H2,4,5,6)/q4*+3;;;/p-12
IUPAC Name
tetrairon(3+) ion tri(phosphonatooxy)phosphonate
SMILES
[Fe+3].[Fe+3].[Fe+3].[Fe+3].[O-]P([O-])(=O)OP([O-])([O-])=O.[O-]P([O-])(=O)OP([O-])([O-])=O.[O-]P([O-])(=O)OP([O-])([O-])=O

Pharmacology

Indication

For the replacement of iron to maintain hemoglobin in adult patients with hemodialysis-dependent chronic kidney disease (HDD- CKD).

Structured Indications
Pharmacodynamics
Not Available
Mechanism of action

Iron delivered into the circulation binds to transferrin for transport to erythroid precursor cells to be incorporated into hemoglobin.

Absorption

The results of the present studies show that micronised, dispersible ferric pyrophosphate is as well absorbed as ferrous sulfate in adults. The absorption of iron depends upon the route of entry. The tissue that first clears parenterally administered iron from the bloodstream determines the bioavailability.

Volume of distribution

Exists in humans almost exclusively complexed to protein or in heme molecules.

Protein binding
Not Available
Metabolism

There is no destructive metabolism of iron because it takes place in a closed system.

Route of elimination

Very little iron is excreted. In normal, healthy adults, some daily loss of iron occurs through normal skin, hair, and nail loss, and GI losses.

Half life

1.48 hours

Clearance
Not Available
Toxicity

Ingestion of less than 40 mg/kg generally does not cause significant toxicity, although mild GI irritation may develop.Mild symptoms are likely to occur with peak iron concentrations greater than 300 mcg/dL, while peak concentrations of more than 500 mcg/dL generally causes severe symptoms.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AlgeldrateAlgeldrate can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
AlmagateAlmagate can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
AlmasilateAlmasilate can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
AloglutamolAloglutamol can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
AluminiumAluminium can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Aluminium acetoacetateAluminium acetoacetate can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Aluminium glycinateAluminium glycinate can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Aluminum hydroxideAluminum hydroxide can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AsenapineAsenapine can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Bismuth SubcitrateBismuth Subcitrate can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Bismuth subnitrateBismuth subnitrate can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Calcium CarbonateCalcium Carbonate can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium silicateCalcium silicate can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
CefdinirThe serum concentration of Cefdinir can be decreased when it is combined with Ferric pyrophosphate.Approved
ChlortetracyclineChlortetracycline can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
CimetidineCimetidine can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CinoxacinThe serum concentration of Cinoxacin can be decreased when it is combined with Ferric pyrophosphate.Approved, Investigational, Withdrawn
DeferiproneThe serum concentration of Deferiprone can be decreased when it is combined with Ferric pyrophosphate.Approved
DemeclocyclineDemeclocycline can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DexlansoprazoleDexlansoprazole can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DexrabeprazoleDexrabeprazole can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
DimercaprolDimercaprol may increase the nephrotoxic activities of Ferric pyrophosphate.Approved
Dipotassium phosphateFerric pyrophosphate can cause a decrease in the absorption of Dipotassium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DolutegravirThe serum concentration of Dolutegravir can be decreased when it is combined with Ferric pyrophosphate.Approved
DoxepinDoxepin can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DoxycyclineDoxycycline can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
EltrombopagThe serum concentration of Eltrombopag can be decreased when it is combined with Ferric pyrophosphate.Approved
EnoxacinThe serum concentration of Enoxacin can be decreased when it is combined with Ferric pyrophosphate.Approved, Investigational
EpinastineEpinastine can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
EsomeprazoleEsomeprazole can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
FamotidineFamotidine can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FleroxacinThe serum concentration of Fleroxacin can be decreased when it is combined with Ferric pyrophosphate.Approved
FlumequineThe serum concentration of Flumequine can be decreased when it is combined with Ferric pyrophosphate.Withdrawn
GarenoxacinThe serum concentration of Garenoxacin can be decreased when it is combined with Ferric pyrophosphate.Investigational
GatifloxacinThe serum concentration of Gatifloxacin can be decreased when it is combined with Ferric pyrophosphate.Approved, Investigational
GemifloxacinThe serum concentration of Gemifloxacin can be decreased when it is combined with Ferric pyrophosphate.Approved, Investigational
GrepafloxacinThe serum concentration of Grepafloxacin can be decreased when it is combined with Ferric pyrophosphate.Investigational, Withdrawn
HydrotalciteHydrotalcite can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental, Investigational
LansoprazoleLansoprazole can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
LevodopaThe serum concentration of Levodopa can be decreased when it is combined with Ferric pyrophosphate.Approved
LevofloxacinThe serum concentration of Levofloxacin can be decreased when it is combined with Ferric pyrophosphate.Approved, Investigational
LevothyroxineThe serum concentration of Levothyroxine can be decreased when it is combined with Ferric pyrophosphate.Approved
Lipoic AcidFerric pyrophosphate can cause a decrease in the absorption of Lipoic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Nutraceutical
MagaldrateMagaldrate can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Withdrawn
Magnesium HydroxideMagnesium Hydroxide can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium oxideMagnesium oxide can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium peroxideMagnesium peroxide can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Magnesium silicateMagnesium silicate can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
Magnesium TrisilicateMagnesium Trisilicate can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
MethanthelineMethantheline can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
MethyldopaThe serum concentration of Methyldopa can be decreased when it is combined with Ferric pyrophosphate.Approved
MetiamideMetiamide can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
MinocyclineMinocycline can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Nalidixic AcidThe serum concentration of Nalidixic Acid can be decreased when it is combined with Ferric pyrophosphate.Approved, Investigational
NemonoxacinThe serum concentration of Nemonoxacin can be decreased when it is combined with Ferric pyrophosphate.Investigational
NizatidineNizatidine can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
NorfloxacinThe serum concentration of Norfloxacin can be decreased when it is combined with Ferric pyrophosphate.Approved
OlanzapineOlanzapine can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
OmeprazoleOmeprazole can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
Oxolinic acidThe serum concentration of Oxolinic acid can be decreased when it is combined with Ferric pyrophosphate.Experimental
PancrelipasePancrelipase can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
PantoprazolePantoprazole can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
PazufloxacinThe serum concentration of Pazufloxacin can be decreased when it is combined with Ferric pyrophosphate.Investigational
PefloxacinThe serum concentration of Pefloxacin can be decreased when it is combined with Ferric pyrophosphate.Approved
PenicillamineFerric pyrophosphate can cause a decrease in the absorption of Penicillamine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Pipemidic acidThe serum concentration of Pipemidic acid can be decreased when it is combined with Ferric pyrophosphate.Experimental
Piromidic acidThe serum concentration of Piromidic acid can be decreased when it is combined with Ferric pyrophosphate.Experimental
PromethazinePromethazine can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
PrulifloxacinThe serum concentration of Prulifloxacin can be decreased when it is combined with Ferric pyrophosphate.Investigational
RabeprazoleRabeprazole can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
RanitidineRanitidine can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
RosoxacinThe serum concentration of Rosoxacin can be decreased when it is combined with Ferric pyrophosphate.Approved, Investigational
Roxatidine acetateRoxatidine acetate can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
RufloxacinThe serum concentration of Rufloxacin can be decreased when it is combined with Ferric pyrophosphate.Experimental
SitafloxacinThe serum concentration of Sitafloxacin can be decreased when it is combined with Ferric pyrophosphate.Experimental, Investigational
Sodium glycerophosphateFerric pyrophosphate can cause a decrease in the absorption of Sodium glycerophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Sodium phosphateFerric pyrophosphate can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SparfloxacinThe serum concentration of Sparfloxacin can be decreased when it is combined with Ferric pyrophosphate.Approved, Investigational
TemafloxacinThe serum concentration of Temafloxacin can be decreased when it is combined with Ferric pyrophosphate.Withdrawn
TriethylenetetramineThe serum concentration of Ferric pyrophosphate can be decreased when it is combined with Triethylenetetramine.Approved
TrovafloxacinThe serum concentration of Trovafloxacin can be decreased when it is combined with Ferric pyrophosphate.Approved, Investigational, Withdrawn
Food Interactions
Not Available

References

General References
  1. Pubchem [Link]
  2. DRUGS.COM [Link]
  3. ChemIDplus [Link]
External Links
PubChem Compound
24877
PubChem Substance
310265060
ChemSpider
23258
ChEBI
132767
Drugs.com
Drugs.com Drug Page
FDA label
Download (238 KB)
MSDS
Download (47 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedPreventionBacterial Infection Due to Helicobacter Pylori (H. Pylori) / Healthy Participants / Non-anemic Children1
1CompletedTreatmentEnd Stage Renal Disease (ESRD)2
1CompletedTreatmentIron-refractory, Iron-deficiency Anemia (IRIDA)1
1Not Yet RecruitingTreatmentAnemias / Chronic Kidney Disease (CKD) / Peritoneal dialysis therapy1
1, 2CompletedTreatmentEnd Stage Renal Disease (ESRD)1
1, 2Not Yet RecruitingTreatmentEnd Stage Renal Disease (ESRD)1
2Active Not RecruitingTreatmentIron-Refractory Iron-Deficiency Anemia1
4Not Yet RecruitingTreatmentAnemias / Bowel Diseases, Inflammatory1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
PowderParenteral272 mg/272mg
PowderParenteral272 mg/1
SolutionHemodialysis; Parenteral272 mg/50mL
SolutionParenteral5.44 mg/mL
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6779468No1996-12-312016-12-31Us
US7816404No2009-04-172029-04-17Us
US6689275No1996-12-312016-12-31Us

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
logP-1.4ChemAxon
pKa (Strongest Acidic)1.7ChemAxon
Physiological Charge-3ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area135.61 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity21.04 m3·mol-1ChemAxon
Polarizability9.03 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Description
This compound belongs to the class of inorganic compounds known as transition metal pyrophosphates. These are inorganic compounds in which the largest oxoanion is pyrophosphate, and in which the heaviest atom not in an oxoanion is a transition metal.
Kingdom
Inorganic compounds
Super Class
Mixed metal/non-metal compounds
Class
Transition metal oxoanionic compounds
Sub Class
Transition metal pyrophosphates
Direct Parent
Transition metal pyrophosphates
Alternative Parents
Inorganic salts / Inorganic oxides
Substituents
Transition metal pyrophosphate / Inorganic oxide / Inorganic salt
Molecular Framework
Not Available
External Descriptors
Not Available

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Oxidorectase activity
General Function
Iron ion binding
Specific Function
Stores iron in a soluble, non-toxic, readily available form. Important for iron homeostasis. Has ferroxidase activity. Iron is taken up in the ferrous form and deposited as ferric hydroxides after ...
Gene Name
FTH1
Uniprot ID
P02794
Uniprot Name
Ferritin heavy chain
Molecular Weight
21225.47 Da
References
  1. uniprot [Link]

Drug created on October 01, 2015 10:55 / Updated on November 09, 2017 04:46